Inositol in the MAnaGemENt of abdominal aortic aneurysm (IMAGEN): study protocol for a randomised controlled trial

Rowbotham, Sophie E.; Pinchbeck, Jenna; Anderson, G.; Bourke, Bernie; Bourke, Michael; Gasser, Thomas C.; Jaeggi, Rene; Jenkins, Jason; Moran, Corey S.; Morton, Sarah; Reid, Christopher M.; Velu, Ramesh; Yip, Lisan; Moxon, Joseph V.; Golledge, Jonathan

doi:10.1186/s13063-017-2304-x

Cited by 2 publications

(1 citation statement)

References 80 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite numerous promising interventions identified in preclinical studies, this substantial investment has not yielded any clinical applications, and currently, there is no medical therapy available for stabilizing growing AAAs. Nevertheless, ongoing clinical studies like IMAGEN trial to evaluate effect of myo-inositol and ARREST trial to investigate the effect of mesenchymal stem cells, are underway to explore potential treatments[ 68 , 69 ].…”

Section: Treatments; Immunological Implicationsmentioning

confidence: 99%

Innovation in pathogenesis and management of aortic aneurysm

Barkhordarian,

Tran,

Menon

et al. 2024

World J Exp Med

View full text Add to dashboard Cite

Aortic aneurysm (AA) refers to the persistent dilatation of the aorta, exceeding three centimeters. Investigating the pathophysiology of this condition is important for its prevention and management, given its responsibility for more than 25000 deaths in the United States. AAs are classified based on their location or morphology. various pathophysiologic pathways including inflammation, the immune system and atherosclerosis have been implicated in its development. Inflammatory markers such as transforming growth factor β, interleukin-1β, tumor necrosis factor-α, matrix metalloproteinase-2 and many more may contribute to this phenomenon. Several genetic disorders such as Marfan syndrome, Ehler-Danlos syndrome and Loeys-Dietz syndrome have also been associated with this disease. Recent years has seen the investigation of novel management of AA, exploring the implication of different immune suppressors, the role of radiation in shrinkage and prevention, as well as minimally invasive and newly hypothesized surgical methods. In this narrative review, we aim to present the new contributing factors involved in pathophysiology of AA. We also highlighted the novel management methods that have demonstrated promising benefits in clinical outcomes of the AA.

show abstract

Section: Treatments; Immunological Implicationsmentioning

confidence: 99%

Innovation in pathogenesis and management of aortic aneurysm

Barkhordarian,

Tran,

Menon

et al. 2024

World J Exp Med

View full text Add to dashboard Cite

show abstract

Pharmacologic Management of Aneurysms

Lindeman

Matsumura

2019

Circulation Research

View full text Add to dashboard Cite

Current management of aortic aneurysms relies exclusively on prophylactic operative repair of larger aneurysms. Great potential exists for successful medical therapy that halts or reduces aneurysm progression and hence alleviates or postpones the need for surgical repair. Preclinical studies in the context of abdominal aortic aneurysm (AAA) identified hundreds of candidate strategies for stabilization, and data from pre-operative clinical intervention studies show that interventions in the pathways of the activated inflammatory and proteolytic cascades in enlarging AAA are feasible. Similarly, extensive series of studies in the murine models of Marfan syndromerelated aortapathy inherited aortic root aneurysm support the concept of pharmaceutical aorta stabilization in Marfan syndrome.Although some clinical studies report successful medical stabilization of growing aortic aneurysms and aortic root stabilization in Marfan syndrome, these claims are not consistently confirmed in larger and controlled studies. Consequently, no medical therapy can be recommended for the stabilization of aortic aneurysms.The discrepancy between preclinical successes and clinical trial failures implies shortcomings in the available models of aneurysm disease, and perhaps incomplete understanding of the pathologic processes involved in later stages of aortic aneurysm progression. Preclinical models more reflective of human pathophysiology, identification of biomarkers to predict severity of disease progression, and improved design of clinical trials may more rapidly advance the opportunities in this important field.

show abstract

Inositol in the MAnaGemENt of abdominal aortic aneurysm (IMAGEN): study protocol for a randomised controlled trial

Cited by 2 publications

References 80 publications

Innovation in pathogenesis and management of aortic aneurysm

Innovation in pathogenesis and management of aortic aneurysm

Pharmacologic Management of Aneurysms

Contact Info

Product

Resources

About